Gilead Sciences Completes Acquisition of MiroBio
September 20 2022 - 4:30PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the
completion of the previously announced transaction to acquire
MiroBio, a privately held U.K.-based biotechnology company focused
on restoring immune balance with agonists targeting immune
inhibitory receptors, for approximately $405 million in cash. The
acquisition provides Gilead with MiroBio’s proprietary discovery
platform and entire portfolio of immune inhibitory receptor
agonists. MiroBio’s lead investigational antibody, MB272, is a
selective agonist of immune inhibitory receptor B- and T-Lymphocyte
Attenuator (BTLA) and has entered Phase 1 clinical trials, with the
first patient dosed in early August 2022. MB272 targets T, B and
dendritic cells to inhibit or blunt activation and suppress an
inflammatory immune response.
“Inflammation is a key area of focus for Gilead, and MiroBio’s
novel discovery platform technology and pipeline provides the
opportunity to develop potentially best-in-class large molecule
therapeutics to help patients with currently unmet medical needs,”
said Flavius Martin, Executive Vice President, Research, Gilead
Sciences. “This novel approach to inflammatory diseases has the
potential to be an important part of providing durable remission
for patients living with complex and chronic immune-mediated
conditions.”
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis, inflammation and cancer. Gilead operates in more
than 35 countries worldwide, with headquarters in Foster City,
California.
Gilead Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including difficulties or unanticipated expenses in connection with
integrating the companies, including the effects of the transaction
on relationships with employees, other business partners or
governmental entities; the risk that Gilead may not realize the
expected benefits of this transaction; the ability of Gilead to
advance MiroBio’s product pipeline and successfully commercialize
MiroBio’s products; the ability of the parties to initiate and
complete clinical trials involving such products in the currently
anticipated timelines or at all; the possibility of unfavorable
results from one or more of such trials involving such products;
uncertainties relating to regulatory applications and related
filing and approval timelines, including the risk that FDA may not
approve any such products in the anticipated indications or on the
timelines or at all, and any marketing approvals, if granted, may
have significant limitations on its use; any assumptions underlying
any of the foregoing; and other risks and uncertainties detailed
from time to time in Gilead’s periodic reports filed with the U.S.
Securities and Exchange Commission (the “SEC”), including current
reports on Form 8-K, quarterly reports on Form 10-Q and annual
reports on Form 10-K. These risks, uncertainties and other factors
could cause actual results to differ materially from those referred
to in the forward-looking statements. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties and are cautioned not to place
undue reliance on these forward-looking statements. All
forward-looking statements are based on information currently
available to Gilead, and Gilead assumes no obligation and disclaims
any intent to update any such forward-looking statements.
Gilead and the Gilead logo are trademarks of
Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit
the company’s website at www.gilead.com, follow Gilead on Twitter
(@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220919005772/en/
Jacquie Ross, Investors Investor_relations@gilead.com
Cathy Cantone, Media (908) 327-3013
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024